• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

From NAFLD to MASLD: Promise and pitfalls of a new definition †.

作者信息

Cusi Kenneth, Younossi Zobair, Roden Michael

机构信息

Division of Endocrinology, Diabetes and Metabolism The University of Florida, Gainesville, FL, USA.

Global NASH Council Center for Outcomes Research in Liver Diseases, Washington DC, USA.

出版信息

Hepatology. 2024 Feb 1;79(2):E13-E15. doi: 10.1097/HEP.0000000000000706. Epub 2023 Dec 19.

DOI:10.1097/HEP.0000000000000706
PMID:38112428
Abstract
摘要

相似文献

1
From NAFLD to MASLD: Promise and pitfalls of a new definition †.从非酒精性脂肪性肝病到代谢功能障碍相关脂肪性肝病：新定义的前景与陷阱†
Hepatology. 2024 Feb 1;79(2):E13-E15. doi: 10.1097/HEP.0000000000000706. Epub 2023 Dec 19.
2
Reply: 'From NAFLD to MASLD: Promise and pitfalls of a new definition' †.回复：“从非酒精性脂肪性肝病到代谢相关脂肪性肝病：新定义的前景与陷阱” †
Hepatology. 2024 Feb 1;79(2):E16-E17. doi: 10.1097/HEP.0000000000000705. Epub 2023 Dec 19.
3
From NAFLD to MASLD: Promise and pitfalls of a new definition.从非酒精性脂肪性肝病到代谢功能障碍相关脂肪性肝病：新定义的前景与陷阱
J Hepatol. 2024 Jul;81(1):e18-e19. doi: 10.1016/j.jhep.2023.09.038. Epub 2023 Dec 19.
4
From NAFLD to MASLD: Promise and pitfalls of a new definition.从非酒精性脂肪性肝病到代谢相关脂肪性肝病：新定义的前景与陷阱
Ann Hepatol. 2024 Jul-Aug;29(4):101179. doi: 10.1016/j.aohep.2023.101179. Epub 2023 Dec 19.
5
Reply to: "From NAFLD to MASLD: Promise and pitfalls of a new definition'.回复：“从非酒精性脂肪性肝病到代谢功能障碍相关脂肪性肝病：新定义的前景与陷阱”
Ann Hepatol. 2024 Jul-Aug;29(4):101178. doi: 10.1016/j.aohep.2023.101178. Epub 2023 Dec 19.
6
Reply to: "From NAFLD to MASLD: Promise and pitfalls of a new definition": EASL, AASLD and ALEH stand united to advance the field of steatotic liver disease.回复：“从非酒精性脂肪性肝病到代谢相关脂肪性肝病：新定义的前景与陷阱”：欧洲肝脏研究学会（EASL）、美国肝病研究学会（AASLD）和阿卜杜勒阿齐兹国王肝脏研究与移植中心（ALEH）联合起来推动脂肪性肝病领域的发展。
J Hepatol. 2024 Jul;81(1):e20-e21. doi: 10.1016/j.jhep.2023.10.008. Epub 2023 Dec 19.
7
Changing from NAFLD to MASLD: Similar cumulative incidence of reflux esophagitis between NAFLD and MASLD.从非酒精性脂肪性肝病转变为代谢功能障碍相关脂肪性肝病：非酒精性脂肪性肝病和代谢功能障碍相关脂肪性肝病之间反流性食管炎的累积发病率相似。
Clin Mol Hepatol. 2024 Jan;30(1):121-123. doi: 10.3350/cmh.2023.0437. Epub 2023 Dec 4.
8
Can we use old NAFLD data under the new MASLD definition?在新的代谢相关脂肪性肝病（MASLD）定义下，我们能否使用旧的非酒精性脂肪性肝病（NAFLD）数据？
J Hepatol. 2024 Feb;80(2):e54-e56. doi: 10.1016/j.jhep.2023.07.021. Epub 2023 Aug 2.
9
[Diagnosis and evaluation of metabolic dysfunction associated steatotic liver disease (MASLD)].代谢功能障碍相关脂肪性肝病（MASLD）的诊断与评估
Rev Med Interne. 2024 Jan;45(1):41-47. doi: 10.1016/j.revmed.2023.10.438. Epub 2023 Dec 29.
10
Changing from NAFLD to MASLD: The new definition can more accurately identify individuals at higher risk for diabetes.从非酒精性脂肪性肝病转变为代谢功能障碍相关脂肪性肝病：新定义能够更准确地识别出糖尿病风险较高的个体。
J Hepatol. 2024 Feb;80(2):e85-e87. doi: 10.1016/j.jhep.2023.09.035. Epub 2023 Oct 10.

引用本文的文献

1
Non-alcoholic fatty liver disease risk with GLP-1 receptor agonists and SGLT-2 inhibitors in type 2 diabetes: a nationwide nested case-control study.在 2 型糖尿病中，GLP-1 受体激动剂和 SGLT-2 抑制剂与非酒精性脂肪性肝病风险的关系：一项全国性巢式病例对照研究。
Cardiovasc Diabetol. 2024 Oct 17;23(1):367. doi: 10.1186/s12933-024-02461-2.
2
Interplay of Cardiometabolic Syndrome and Biliary Tract Cancer: A Comprehensive Analysis with Gender-Specific Insights.心血管代谢综合征与胆道癌的相互作用：一项具有性别特异性见解的综合分析。
Cancers (Basel). 2024 Oct 9;16(19):3432. doi: 10.3390/cancers16193432.
3
Targeting hepatic macrophages for non-alcoholic fatty liver disease therapy.
以肝脏巨噬细胞为靶点治疗非酒精性脂肪性肝病
Front Cell Dev Biol. 2024 Sep 5;12:1444198. doi: 10.3389/fcell.2024.1444198. eCollection 2024.
4
Impairment of health-related quality of life among people with type 2 diabetes and advanced liver fibrosis.2 型糖尿病合并晚期肝纤维化患者的健康相关生活质量受损。
Sci Rep. 2024 Sep 17;14(1):21650. doi: 10.1038/s41598-024-72105-8.
5
Dysregulated bile acid homeostasis: unveiling its role in metabolic diseases.胆汁酸稳态失调：揭示其在代谢性疾病中的作用。
Med Rev (2021). 2024 Jun 4;4(4):262-283. doi: 10.1515/mr-2024-0020. eCollection 2024 Aug.
6
Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases.代谢功能障碍相关脂肪性肝病（MASLD）和代谢功能障碍相关脂肪性肝炎（MASH）对心脏、肌肉和肾脏相关疾病的全身影响。
Front Cell Dev Biol. 2024 Jul 16;12:1433857. doi: 10.3389/fcell.2024.1433857. eCollection 2024.
7
Therapeutic implications for sphingolipid metabolism in metabolic dysfunction-associated steatohepatitis.代谢相关脂肪性肝炎中鞘脂代谢的治疗意义。
Front Endocrinol (Lausanne). 2024 Jun 19;15:1400961. doi: 10.3389/fendo.2024.1400961. eCollection 2024.
8
Diffuse and focal liver fat: advanced imaging techniques and diagnostic insights.弥漫性和局灶性肝脂肪变：先进的影像学技术和诊断见解。
Abdom Radiol (NY). 2024 Dec;49(12):4437-4462. doi: 10.1007/s00261-024-04407-4. Epub 2024 Jun 19.
9
Envisioning how to advance the MASH field.展望如何推动 MASH 领域的发展。
Nat Rev Gastroenterol Hepatol. 2024 Oct;21(10):726-738. doi: 10.1038/s41575-024-00938-9. Epub 2024 Jun 4.
10
The Cardiac-Kidney-Liver (CKL) syndrome: the "real entity" of type 2 diabetes mellitus.心肾肝（CKL）综合征：2型糖尿病的“真实实体”。
Arch Med Sci. 2024 Jan 31;20(1):207-215. doi: 10.5114/aoms/183070. eCollection 2024.